Lundbeck announces last patient randomized in DEEp OCEAN, a large Phase III trial in developmental and epileptic encephalopathies (DEEs)

Phase 3bexicaserinPositive

AI Analysis

Summary

Lundbeck announced the last patient has been randomized in the DEEp OCEAN Phase III trial evaluating bexicaserin for treating seizures in developmental and epileptic encephalopathies. The trial is described as the broadest pivotal study to date, enrolling patients across a wide range of DEE syndromes.

Clinical Trial Data

Phase

Outcome Details

Last patient randomized in DEEp OCEAN trial

Importance:5/10

Sentiment:

0.30

Phase 3epilepsydevelopmental and epileptic encephalopathiesclinical trial milestone

Related Companies

$HLUYY

Read the original article

Published by PR Newswire Biotech on July 20, 2026 7:46 AM

Read Original